Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Ambroxol salbutamol lipid solid dispersion

A technology of ambroxol salbutamol and solid dispersion, applied in directions such as liposome delivery, oil/fat/wax inactive ingredients, organic active ingredients, etc., can solve problems such as no reports on lipid solid dispersions, and achieve therapeutic Respiratory system diseases, significant effect, stable quality effect

Inactive Publication Date: 2016-04-20
CP PHARMA QINGDAO CO LTD
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Dosage forms such as solutions and granules containing ambroxol hydrochloride and salbutamol sulfate already exist in the prior art, but there is no report of lipid solid dispersion

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ambroxol salbutamol lipid solid dispersion
  • Ambroxol salbutamol lipid solid dispersion
  • Ambroxol salbutamol lipid solid dispersion

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Mix 25% glyceryl trilaurate, 30% coconut oil, 15% polyethylene glycol caprylic acid / capric glyceride, 20% vitamin E acetate and 10% PEG200 to obtain a lipid carrier, 30% micropowder silica gel and Mix 70% cornstarch uniformly to obtain a solid carrier, pulverize 15g of ambroxol hydrochloride and 20g of salbutamol sulfate through a 120 mesh sieve, add 5g of butylated hydroxyanisole and mix uniformly to obtain a drug mixture, and the drug mixture is in a mass ratio of 1:1000 Add to the molten lipid carrier, vortex, ultrasonic for 30min to dissolve evenly, to obtain the lipid mixture, add the lipid mixture in the molten state to the solid carrier whose mass is 1:2 with the lipid carrier to absorb and solidify .

Embodiment 2

[0022] Mix 25% glyceryl trilaurate, 30% coconut oil, 15% polyethylene glycol caprylic acid / capric glyceride, 20% vitamin E acetate and 10% PEG200 to obtain a lipid carrier, 30% micropowder silica gel and Mix 70% cornstarch uniformly to obtain a solid carrier, pulverize 15g of ambroxol hydrochloride and 20g of salbutamol sulfate through a 120 mesh sieve, add 5g of butylated hydroxyanisole and mix uniformly to obtain a drug mixture, and the drug mixture is in a mass ratio of 1:1500 Add to the molten lipid carrier, vortex and ultrasonic for 30 minutes to dissolve evenly to obtain a lipid mixture, add the lipid mixture in a molten state to a solid carrier with a mass of lipid carrier of 1:3 to absorb and solidify .

Embodiment 3

[0024] Mix 25% glyceryl trilaurate, 30% coconut oil, 15% polyethylene glycol caprylic acid / capric glyceride, 20% vitamin E acetate and 10% PEG200 to obtain a lipid carrier, 30% micropowder silica gel and Mix 70% cornstarch uniformly to obtain a solid carrier, pulverize 15g of ambroxol hydrochloride and 20g of salbutamol sulfate through a 120 mesh sieve, add 5g of butylated hydroxyanisole and mix uniformly to obtain a drug mixture, and the drug mixture is in a mass ratio of 1:2000 Add to the molten lipid carrier, vortex and ultrasonic for 30 minutes to dissolve evenly to obtain a lipid mixture, add the lipid mixture in a molten state to a solid carrier with a mass ratio of 1:4 to the lipid carrier to absorb and solidify .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an ambroxol salbutamol lipid solid dispersion and a preparing method thereof, belonging to the field of medicinal preparations. The lipid solid dispersion contains ambroxol hydrochloride, salbutamol sulfate and butyl hydroxy anisol, a lipid carrier is a mixture of 25% of laurin, 30% of coconut oil, 15% of polyethylene glycol octanoic acid / caprin, 20% of vitamin E acetate and 10% of PEG200, a solid carrier is a mixture of 30% of aerosol and 70% of corn starch, and the ambroxol salbutamol lipid solid dispersion is stable in quality, obvious in effect and capable of effectively treating diseases of the respiratory system such as acute and chronic bronchitis and asthma.

Description

technical field [0001] The invention relates to the field of pharmaceutical preparations, in particular to an ambroxoxalbutamol lipid solid dispersion and a preparation method thereof. Background technique [0002] Respiratory system disease is a common and frequently-occurring disease. The main lesions are in the trachea, bronchi, lungs, and chest cavity. Mild cases often cause coughing, chest pain, and respiratory problems. Severe cases have dyspnea, hypoxia, and even death due to respiratory failure. The death rate in the city is the third, while in the countryside it is the first. What should be paid more attention to is that due to air pollution, smoking, population aging and other factors, chronic obstructive pulmonary disease (referred to as COPD, including chronic bronchitis, emphysema, pulmonary heart disease), bronchial asthma, lung cancer, etc. , Pulmonary diffuse interstitial fibrosis, and the morbidity and mortality of diseases such as pulmonary infection are i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/137A61K9/127A61K47/44A61P11/00A61P11/06
CPCA61K31/137A61K9/1277A61K47/44A61K2300/00
Inventor 王明刚陈阳生任莉
Owner CP PHARMA QINGDAO CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com